Categories: News

Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SYDNEY, AUSTRALIA / ACCESSWIRE / July 14, 2021 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Thursday, 5th August 2021 at 8:30 a.m. (Australian Eastern Standard Time)

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM

Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:

Thursday, 5th August 2021 at 8:30 a.m. (Australian Eastern Standard Time)

The meeting is to be held in person at the Company’s headquarters: First Floor, Unit 4, 476 Gardeners Road, Alexandria NSW, 2015, Australia

For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click:

https://cdn.newswire.com/files/x/23/2b/87fa86409309a37e73d53767463b.pdf

For a link to the full set of audited Financial Statements for the Year Ended 31 December 2020, please click:

https://cdn.newswire.com/files/x/d0/44/b9ae3fddebc6b71c5ea96f99b938.pdf

_________________________________

30 June 2021

Dear Shareholder,

On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at our Annual General Meeting (AGM), which has been scheduled as follows:

Date: Thursday, 5th August 2021 (AEST)
Time: 8:30 a.m. (AEST)
Venue: Held by physical attendance at: First Floor, Unit 4 Century Estate, 476 Gardeners Road, Alexandria, NSW, 2015

Outline of the items of business

At this AGM, we will provide an opportunity for shareholders to consider the following:

  • the Company’s financial statements and related documents for the year ended December 31, 2020;
  • ratification of the appointment of the Company auditor; and
  • re-election of Dr. Alan Bell as a director of the Company.

Details of these items are contained in the enclosed Notice of AGM and Explanatory Memorandum.

Voting at the AGM or by proxy

A proxy form accompanies the enclosed Notice of AGM. If you wish to attend the AGM in person, please bring a copy of the proxy form with you. Registration will be available from 8:00 a.m. (AEST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of AGM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.

If you have any difficulties placing your vote via proxy please do not hesitate to contact Brad McCarthy at brad.mccarthy@parnell.com or call +612 9667 4411.

Yours sincerely,

Alan Bell
Chairman

Related Files

Parnell 2021 Notice of Annual General Meeting and Ex Mem – Final.pdf

Parnell 2020 Financial Statements – Final Executed (30.4.21).pdf

Related Images

 

SOURCE: Parnell 

View source version on accesswire.com:
https://www.accesswire.com/655510/Parnell-Pharmaceuticals-Gives-Notice-of-Annual-General-Meeting-and-Explanatory-Memorandum

Staff

Recent Posts

LEGACY EDUCATION INC. ACHIEVES RECORD Q3 WITH 50% REVENUE GROWTH AND SURPASSES 3,000 ENROLLED STUDENTS

LANCASTER, Calif., May 15, 2025 /PRNewswire/ -- Legacy Education Inc. (NYSE American: LGCY), a leading…

11 hours ago

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW…

11 hours ago

MediKarma Aligns with CMS National Preventive Health Strategy Through AI-Driven, Prevention-First Implementation Infrastructure

SAN FRANCISCO, May 15, 2025 /PRNewswire/ -- MediKarma, a digital health company specializing in AI-powered…

11 hours ago

Dentegrate AI Powers Growth for 220+ Dental Practices, Doubling New Patient Acquisition

BOSTON, May 15, 2025 /PRNewswire/ -- Dentegrate AI is revolutionizing dental practice growth, with over…

11 hours ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating…

12 hours ago

cbdMD Delivers Continued Revenue Growth and Trend Towards Profitability in Second Fiscal Quarter

Successfully Completes Capital Structure Reset with Series A Preferred ConversionCharlotte, North Carolina--(Newsfile Corp. - May…

12 hours ago